Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, Translarna will be withdrawn from the market in EU countries. However, it will remain available in the UK, Russia, and several countries in the Middle East and South America (Bello et al., 2025).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Bello et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–28. · DOI · Paper page
- McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451–61. https://doi.org/10.1016/S0140-6736(17)32160-8. · DOI · Paper page
- Bello L, D’Angelo G, Villa M, et al. Genetic modifiers of respiratory function in Duchenne muscular dystrophy. Ann Clin Transl Neurol. 2020;7(5):786–98. https://doi.org/10.1002/acn3.51046. · DOI
- Birnkrant DJ, Bello L, Butterfield RJ, et al. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022;10(4):403–20. https://doi.org/10.1016/S2213-2600(21)00581-6. · DOI
- Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen GJB, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006;34(2):135–44. https://doi.org/10.1002/mus.20586. · DOI · Paper page
- Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447(7140):87–91. https://doi.org/10.1038/nature05756. · DOI · Paper page
- Finkel RS, Flanigan KM, Wong B, et al. Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS ONE. 2013;8(12): e81302. https://doi.org/10.1371/journal.pone.0081302. · DOI · Paper page
- Bushby K, Finkel R, Wong B, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477–87. https://doi.org/10.1002/mus.24332. · DOI · Paper page
- McDonald CM, Campbell C, Torricelli RE, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489–98. https://doi.org/10.1016/S0140-6736(17)31611-2. · DOI · Paper page
- McDonald CM, Wu S, Gulati S, et al. Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3, randomized, double-blind, placebo-controlled trial (PL5.001). Neurology. 2023. https://doi.org/10.1212/WNL.0000000000202505. · doi:10.1212/wnl.0000000000202505
- MDA Clinical & Scientific Conference. Ataluren slows the decline of muscle function in patients with nmDMD: a meta-analysis of three randomized, double-blind, placebo-controlled trials [poster]. https://www.mdaconference.org/abstract-library/ataluren-slows-the-decline-of-muscle-function-in-patients-with-nmdmd-a-meta-analysis-of-three-randomized-double-blind-placebo-controlled-trials/. Accessed 13 May 2025.
- Campbell C, Barohn RJ, Bertini E, et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J Comp Eff Res. 2020;9(14):973–84. https://doi.org/10.2217/cer-2020-0095. · DOI
- Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393–403. https://doi.org/10.1016/S1474-4422(24)00036-X. · DOI
- Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31(1):332–41. https://doi.org/10.1038/s41591-024-03304-z. · DOI · Paper page
- Mercuri E, Osorio AN, Muntoni F, et al. Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis. J Neurol. 2023;270(8):3896–913. https://doi.org/10.1007/s00415-023-11687-1. · doi:10.1007/s00415-023-11687-1
- McDonald CM, Henricson EK, Abresch RT, et al. The cooperative international neuromuscular research group Duchenne natural history study: a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32–54. https://doi.org/10.1002/mus.23807. · DOI · Paper page
- Muntoni F, Buccella F, Osorio AN, et al. 395P Age at loss of ambulation in patients with nmDMD from the STRIDE Registry: sensitivity analyses. Neuromuscul Disord. 2024;43(S1):104441.123. https://doi.org/10.1016/j.nmd.2024.07.132. · doi:10.1016/j.nmd.2024.07.132
- Gloss D, Moxley RT, Ashwal S, Oskoui M. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465–72. https://doi.org/10.1212/WNL.0000000000002337. · DOI · Paper page
- Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17(4):347–61. https://doi.org/10.1016/S1474-4422(18)30025-5. · DOI · Paper page
- Muntoni F, Signorovitch J, Sajeev G, et al. DMD genotypes and motor function in Duchenne muscular dystrophy: a multi-institution meta-analysis with implications for clinical trials. Neurology. 2023;100(15):e1540–54. https://doi.org/10.1212/WNL.0000000000201626. · DOI · Paper page
- Bello L, Morgenroth LP, Gordish-Dressman H, Hoffman EP, McDonald CM, Cirak S. DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology. 2016;87(4):401–9. https://doi.org/10.1212/WNL.0000000000002891. · DOI · Paper page
- Torella A, Zanobio M, Zeuli R, et al. The position of nonsense mutations can predict the phenotype severity: a survey on the DMD gene. PLoS ONE. 2020;15(8): e0237803. https://doi.org/10.1371/journal.pone.0237803. · DOI
- Ricotti V, Muntoni F, Voit T. Challenges of clinical trial design for DMD. Neuromuscul Disord. 2015;25(12):932–5. https://doi.org/10.1016/j.nmd.2015.10.007. · doi:10.1016/j.nmd.2015.10.007
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Bello, L., Riguzzi, P., Albamonte, E., Astrea, G., Battini, R., Barp, A., Berardinelli, A. L., Bertini, E. S., Brolatti, N., Bruno, C., Corti, S., D’Amico, A., D’Angelo, M. G., Dallavalle, G., Liguori, R., Maggi, L., Magri, F., Mancuso, M., Masson, R., Mercuri, E., Minetti, C., Messina, S., Mongini, T., Musumeci, O., Nigro, V., Pane, M., Panicucci, C., Pedemonte, M., Pini, A., Politano, L., Previtali, S., Ricci, F., Ricci, G., Ruggiero, L., Sansone, V., Siciliano, G., Trabacca, A., Trucco, F., Velardo, D., Pegoraro, E., & Comi, G. P.
- ORCID
- Bello, Luca
- Venue
- Drugs in R&D
- Published
- 2025-05-28
- Volume
- 25
- Issue
- 2
- Pages
- 99-106
- ISSN
- 1174-5886
- 1179-6901
- Cited by
- 8
- References
- 0
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy. https://app.cochat.ai/papers/10.1007/s40268-025-00512-x
- The paper
- Bello, L., Riguzzi, P., Albamonte, E., Astrea, G., Battini, R., Barp, A., Berardinelli, A. L., Bertini, E. S., Brolatti, N., Bruno, C., Corti, S., D’Amico, A., D’Angelo, M. G., Dallavalle, G., Liguori, R., Maggi, L., Magri, F., Mancuso, M., Masson, R., . . . Comi, G. P. (2025). Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy. Drugs in R&D. https://doi.org/10.1007/s40268-025-00512-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.